China, Japan grant patents to Galectin Therapeutics
Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis (NASH) cirrhosis and cancer, has received two new patents in China and two new patents in Japan for the company’s lead compound, GR-MD-02. It is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases.
The two patents from China provide broad intellectual property coverage. The first patent covers GR-MD-02 composition of matter and methods of use broadly for the treatment of fibrosis, inflammatory and autoimmune disorders, or cancer. The second patent extends the use of GR-MD-02 to a variety of other diseases including neurodegenerative disease, psoriasis, cutaneous and systemic lupus erythematosus, systemic sclerosis (scleroderma) and dermatitis.
The two new Japanese patents, in combination with the company’s two existing Japanese patents, provide broad intellectual property coverage including GR-MD-02 composition of matter and all potential therapeutic indications under development in this important pharmaceutical market.